BREAKING NEWS!: PCF funded drug Enzalutamide approved for new use in men with NMCRPC. Read More.
2015 was as an exceptional year for science — in particular, genetics-based science that will directly affect the care and improve the outcome for prostate cancer patients worldwide. Read More
We're in the midst of a revolution in how prostate cancer is treated — and it's being led by new knowledge about the genes behind the disease. Read More